Angiotensin-converting enzyme 2 is an essential regulator of heart function

被引:1439
作者
Crackower, MA
Sarao, R
Oudit, GY
Yagil, C
Kozieradzki, I
Scanga, SE
Oliveira-dos-Santos, AJ
da Costa, J
Zhang, LY
Pei, Y
Scholey, J
Ferrario, CM
Manoukian, AS
Chappell, MC
Backx, PH
Yagil, Y
Penninger, JM
机构
[1] Univ Toronto, Ontario Canc Inst, Amgen Res Inst, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada
[3] Univ Toronto, Dept Immunol, Toronto, ON M5G 2M9, Canada
[4] Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence Cardi, Toronto, ON M5G 2M9, Canada
[5] Univ Toronto, Dept Physiol, Toronto, ON M5G 2M9, Canada
[6] Univ Toronto, Dept Med, Toronto, ON M5G 2M9, Canada
[7] Univ Toronto, Univ Hlth Network, Toronto, ON M5G 2M9, Canada
[8] Univ Toronto, Ontario Canc Inst, Univ Hlth Network, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada
[9] Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A-1030 Vienna, Austria
[10] Ben Gurion Univ Negev, Barzilai Med Ctr, Fac Hlth Sci, Dept Nephrol & Hypertens,Lab Mol Med, IL-78306 Ashqelon, Israel
[11] Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Dis Ctr, Winston Salem, NC 27157 USA
基金
以色列科学基金会; 加拿大健康研究院;
关键词
D O I
10.1038/nature00786
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cardiovascular diseases are predicted to be the most common cause of death worldwide by 2020. Here we show that angiotensin-converting enzyme 2 (ace2) maps to a defined quantitative trait locus (QTL) on the X chromosome in three different rat models of hypertension. In all hypertensive rat strains, ACE2 messenger RNA and protein expression were markedly reduced, suggesting that ace2 is a candidate gene for this QTL. Targeted disruption of ACE2 in mice results in a severe cardiac contractility defect, increased angiotensin II levels, and upregulation of hypoxia-induced genes in the heart. Genetic ablation of ACE on an ACE2 mutant background completely rescues the cardiac phenotype. But disruption of ACER, a Drosophila ACE2 homologue, results in a severe defect of heart morphogenesis. These genetic data for ACE2 show that it is an essential regulator of heart function in vivo.
引用
收藏
页码:822 / 828
页数:7
相关论文
共 42 条
[1]   Differential actions of renal ischemic injury on the intrarenal angiotensin system [J].
Allred, AJ ;
Chappell, MC ;
Ferrario, CM ;
Diz, DI .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2000, 279 (04) :F636-F645
[2]   Segmentation and specification of the Drosophila mesoderm [J].
Azpiazu, N ;
Lawrence, PA ;
Vincent, JP ;
Frasch, M .
GENES & DEVELOPMENT, 1996, 10 (24) :3183-3194
[3]   Endothelial dysfunction in cardiovascular diseases - The role of oxidant stress [J].
Cai, H ;
Harrison, DG .
CIRCULATION RESEARCH, 2000, 87 (10) :840-844
[4]   Essential hypertension Part I: Definition and etiology [J].
Carretero, OA ;
Oparil, S .
CIRCULATION, 2000, 101 (03) :329-335
[5]   EVIDENCE FOR AN INTRINSIC ANGIOTENSIN SYSTEM IN THE CANINE PANCREAS [J].
CHAPPELL, MC ;
MILLSTED, A ;
DIZ, DI ;
BROSNIHAN, KB ;
FERRARIO, CM .
JOURNAL OF HYPERTENSION, 1991, 9 (08) :751-759
[6]   CLONING AND EXPRESSION OF AN EVOLUTIONARY CONSERVED SINGLE-DOMAIN ANGIOTENSIN-CONVERTING ENZYME FROM DROSOPHILA-MELANOGASTER [J].
CORNEL, MJ ;
WILLIAMS, TA ;
LAMANGO, NS ;
COATES, D ;
CORVOL, P ;
SOUBRIER, F ;
HOHEISEL, J ;
LEHRACH, H ;
ISAAC, RE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (23) :13613-13619
[7]  
CORVOL P, 1998, HDB PROTEOLYTIC ENZY, P1066
[8]   A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 [J].
Donoghue, M ;
Hsieh, F ;
Baronas, E ;
Godbout, K ;
Gosselin, M ;
Stagliano, N ;
Donovan, M ;
Woolf, B ;
Robison, K ;
Jeyaseelan, R ;
Breitbart, RE ;
Acton, S .
CIRCULATION RESEARCH, 2000, 87 (05) :E1-E9
[9]   Stroke risk factors and stroke prevention [J].
Elkind, MS ;
Sacco, RL .
SEMINARS IN NEUROLOGY, 1998, 18 (04) :429-440
[10]   Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events [J].
Enseleit, F ;
Hürlimann, D ;
Lüscher, TF .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2001, 37 :S21-S30